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A NEW ANTIFUNGAL ANTIBIOTIC, MYCOSTATIN (NYSTATIN), FOR
THE TREATMENT OF MONILIASIS: A PRELIMINARY REPORT*
MILTON B. SLOANE, M.D.
The increasing use of antibiotics has caused monilial infections to become more common
and of greater concern. The changes these drugs produce in the bacterial flora of the mouth
and gastrointestinal tract are frequently associated with an overgrowth of Candida (moni-
ha albicans. As a result, oral moniliasis (thrush), gastrointestinal moniliasis with perianal
pruritus, and anogenital and vaginal moniliasis are becoming increasingly important prob-
lems to all physicians. The ineffectiveness and unacceptability of presently used antimo-
nilial agents have encouraged the search for better drugs.
In 1950, Hazen and Brown reported the discovery of a new antibiotic, Mycostatin (Nysta-
tin), isolated from Streptomyccs noursei and effective against a wide variety of yeasts and
fungi (1, 2). Animal studies demonstrated its lack of toxicity, its efficacy in vivo, and its
protective effect against the increased virulence of the combination of monilia with the
tetracycline group of antibiotics (3, 4, 5, 6, 7). Stcrnbcrg el al. showed that oral administra-
tion of the antibiotic was well tolerated in man and would abolish or greatly reduce the
number of monilia in the human gastrointestinal tract (3).
The material used, mycostatin (Nystatin) was administered in the following forms:
trochcs, each containing 3,000 units; an ointment containing 50,000 units per gram in Plas-
tibasc® (olcaginous ointment base); a vaginal suppository containing 30,000 units and 1.5
mg. ncomycin and 0.2 mg. gramicidin; and a freshly made solution in propylene glycol con-
taining 150,000 units per ml. The ncomycin present in the suppositories was discounted as a
factor in the antifungal effect, since it has been shown that monilia may flourish in the
presence of neomycin (8).
Case 1: R. B., a laboratory worker, aged 50, was first seen in September 1953, complaining
of burning and soreness of the mouth. She gave a history of having used penicillin lozenges
following extraction of a tooth two days prior to the onset. Examination showed a beefy
red tongue and marked erythema of the buccal mucous membranes. Plate cultures showed
50 colonies of Candida albicans per agar slant. Nystatin trochcs were started, and two days
later, a repeated culture showed 2 colonies per agar slant. The troches were stopped, and
there was a prompt increase in the number of colonies. However, there were no recurrence
of the soreness of the mouth. Since that time, repeated cultures have shown occasional
monilial colonies, but there have been no recurrences of symptoms.
Case 2: An eleven year old girl, otherwise in normal health, except for mild acne, was
first seen on April 9, 1954, following a ten day trip to Mexico. Examination revealed a marked
crythcma of the buccal membranes, gums and hard palate; interspersed about the crythema-
tous areas were whitish plaques. In addition to the eruption, she showed a diffuse area of
crythema in the intcrglutcal folds, with accompanying maceration and white plaques.
Scrapings from both the mouth and intcrglutcal folds showed the presence of many mycclia
and spores. The diagnosis was moniliasis. Dihydroxyiodoquinonc was prescribed locally,
and when seen again on April 22, 1954, there was no change. Nystatin trochcs were given
for the mouth and nystatin ointment was applied to the anopcrincal area. She was seen
again in the following week, when both the mouth and anogcnital areas were entirely nor-
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mal. The patient and her mother concurred in the statement that the eruptiou had com-
pletely disappeared after three days of therapy. There was no further history of recurrence.
Case 3: M. H., a white female, aged 43, was first seen on February 19th, 1954, complaining
of an annoying vaginal discharge which had been present for about two and a half years.
It was most marked premenstrually. Repeated microscopic examinations and cultures
showed only Candida (monilia) albicans. There was no definite history of antecedent anti-
biotic medication. Treatment had consisted of douches, fatty acid gels and gentian violet.
These measures did not control the discharge nor the itching. Physical examination revealed
a mild erythema and maceration, with a moderate white discharge about the external geni-
talia. Speculum examination showed moderately erythematous mucous membranes, with
scattered adherent whitish plaques. She was started ou Nystatin vaginal suppositories
twice a day, and noted a marked, almost immediate cessation of discharge and discomfort.
She was instructed to use the suppositories throughout the menses. Satisfactory response
to the therapy was almost immediate; however, with withdrawal of the therapy the dis-
charge recurred. At the present time, she is obliged to use a suppository every one to two
days in order to suppress the symptoms. Since the institution of the the therapy, the monilia
could not be recultured from material taken from the vaginal tract.
Case 4: W. W., a male aged 46, was first seen on August 16, 1954, with a history of prurtus
ani at frequent intervals for the past two years. The acute symptoms had appeared six weeks
prior to the initial visit, and were so troublesome that he had to stop working. He had re-
ceived a great deal of therapy, including local medication and X-ray therapy. Most of the
local medications proved extremely irritating and had to be stopped after a short time.
One month prior to the initial consultation, he had been operated on for an anal fistula.
Scrapings showed many mycelia and blastospores, and a clinical diagnosis of moniliasis
was made. On physical examination the perianal tissue showed marked maceration and
lichenification, with an area of erosion in one segment. Application of iodochlorhydroxy-
quinoline cream and hydrocortisone ointment produced marked discomfort and had to be
discontinued. On August 23, Nystatin in propylene glycol was started. When seen four days
later, he was entirely free of symptoms and was discharged.
Case 5: A female, aged 30, was first seen on August 10, 1954, with a complaint of severe
vaginal discharge and genital itchings for the past year. There had been no response to
various vaginal jellies and douches. Physical examination showed a thick, milky, vaginal
discharge. The anogenital tissues showed little abnormality. Because of the thick, purulent
quality of the discharge, no attempt was made to obtain a culture. Vaginal Nystatin sup-
positories were prescribed, to be used twice daily. When she was seen one week later, the
discharge had diminished but not entirely disappeared; most striking, was the almost im-
mediate relief of the prnritus. She volunteered that this was the first relief of symptoms she
had experienced in over a year. Repeated efforts to culture the monilia were not successful.
This patient was followed during the subsequent month; the discharge diminished grad-
ually, and when she was last seen, on September 24, there was no discharge present and the
patient was entirely free of symptoms.
Case 6: A female, aged 28, was first seen on August 18, 1954, with a marked erythema aud
maceration in the inguinal and axillary folds. There was no response to terramycin therapy.
Cultures were positive for Candida (moniiia) albicans in the inguinal folds and under the
breasts. On September 10 she was started on Nystatin solution in propylene glycol, and
when seen on September 17, she showed only a minimal residual erythema, and was dis-
charged.
Case 7: A female, aged 63, who was first seen on September 4, 1953, showed fissures at
the corners of her mouth, with white adherent lesions on the buceal membranes and tongue.
Cultures were positive for Candida (monilia) albicans in the angles of the mouth and on the
tongue. On September 11 she was started on Nystatin ointment. When seen the following
week, scrapings were negative. She continued well, under observation, but each time the
medication was stopped she showed a recurrence. On December 17 she showed a chronic
paronychia of the right thumb, from which the monilia was again cultured. On March 24,
NEW ANTIFUNGAL ANTIBIOTIC 571
1954, there was a marked recurrence of the mouth lesion, but the nail had improved some-
what. On April 9, Nystatin troches were prescribed q.i.d., followed by a marked lessening of
symptoms. The symptoms have since been controlled with the Nystatin, but they have
recurred each time the medication was withdrawn. The infected nail showed little change.
Case 8: A. S., a female patient, aged 43, was first seen on September 3, 1954, complaining
of itching and burning of the axillae and inframammary areas, of ten days' duration. Ex-
amination showed a marked erythema and maceration of these areas. Direct examination
of scrapings showed mycelia and blastospores. Cultures were positive for C. (monilia)
albicans. She was instructed to apply I'tystatin in propylene glycol. She reported complete
disappearance of the symptoms within two days. There was a mild recurrence one week
later, with prompt response to the renewed application of the medication, and then no fur-
ther exacerbation. When she was seen one month later, there had been no further recur-
rence.
sUMMARY AND CONCLUSIONS
A preliminary report of the results of treatment of eight cases of moniliasis of the skin
and mucous membranes with a new antifungal antibiotic, Mycostatin (Nystatin) is pre-
sented. Six of the patients apparently cleared completely, and two require continued
therapy to remain free of signs and symptoms. The prompt favorable clinical response,
confirmed by laboratory studies, in these resistant cases warrants the further use and study
of this agent.
Addendum: Attention is called to a previous report on the therapeutic approach: R. C. V.
Robinson: Systemic Moniliasis treated with Mycostatin, J. Invest Dermat. 24: 375, 1955.
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